ClinicalTrials.gg
Status unknownNCT01918384NORTH POLE DMDUpdated Sep 3, 2015

Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy

A Phase 2 interventional study of NPC-14 and Placebo in Muscular Dystrophy, Duchenne, sponsored by Kobe University. Status unknown at 4 sites in Japan. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2015-09-03.

Sponsored by Kobe University · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2015), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
4 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan — 2 open to participants now, 9 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · Japan.

Planned enrollment
18th of 26
21 · median 62
Started
2013
with 2 others
Phase 2
8 of 27
1 open now
Registered
6th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, this one is the 18th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2013, is one of 8 in phase 2, and was the 6th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

2 of the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, or all of them as a file.
02

Study summary

Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.

03

Conditions studied

  • Muscular Dystrophy, Duchenne

Keywords

  • Duchenne muscular dystrophy
  • NPC-14
  • Arbekacin
  • nonsense
  • readthrough
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of DMD resulting from a nonsense mutation by whole genome sequencing of the dystrophin gene
  2. To have intact right or left biceps muscles, or an alternative muscle group that is able to be underwent for appropriate evaluation of efficacy
  3. To meet the following criteria at screening (baseline visit), within 30 days prior to the first dose of study drug

    • Ambulant and able to walk at least 75 meters during the 6MWT
    • Able to comply with and complete all protocol requirements, and judged by the investigator to be appropriate to participate in the study from the screening results
  4. Aged at least 4 years at the time of giving
  5. Male
  6. Able to be hospitalized for the study requirement
  7. Signed Informed consent by parents/legal guardian and/or signed assent by the subject (age of assent to be determined by IRB)

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to medicines that have a potential of restoring dystrophin or other functional protein (readthrough, exon skipping, utrophin upregulation therapy etc.)
  2. Known mutation at nucleotide 1555 in 12S rRNA gene of mitochondrial DNA, and/or personally or families have been treated or have a history of eight cranial nerve disorder (hearing loss、vertigo、tinnitus etc.)as a result of aminoglycoside use
  3. Inability to hear within the range of 0 to 25 dB by pure tone audiometry, abnormalities on auditory brainstem response audiometry, and/or loss of frequency by distortion product oto acoustic emissions at screening
  4. Poor oral intake or enable to oral intake, and/or bad general status
  5. Known allergies to NPC-14, other aminoglycosides, and/or bacitracin
  6. Presence of anti-dystrophin antibody at the baseline assessments
  7. Cys-C ≥1.2 mg/L and/or creatinine concentration >1.5 times the upper limit of age corrected normal range
  8. (EF) \<40% or left ventricular fractional shortening (FS) \<25%, and/or ≥480 msec (corrected QT interval by Fridericia's method)
  9. Need of mechanical ventilation
  10. Forced vital capacity (FVC) \<50% predicted
  11. concomitant diseases (hematology, psychoneurotic, hepatic, pulmonary, endocrine, immune, renal, and gastroenterological diseases), and/or cancer
  12. Impairment of intellectual functions, and/or expressive language ability which might interfere with study assessments
  13. Treatment with other systemic aminoglycoside within 6 months prior to the first administration of study drug
  14. Initiation of systemic glucocorticosteroids treatment, and/or start exercise cure, physical therapy, or occupational therapy which might interfere with study assessments. Changing of dose and schedule of systemic glucocorticosteroids within 6 months prior to the first administration of study drug
  15. History of any surgical procedure within months prior to the first administration of study drug or have a plan during study
  16. History of sever allergy from food and medicine like an anaphylaxis shock or generalized rash
  17. Participation in any other clinical trial and intake of any investigational drug within 6month of study entry
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    NPC-14

    Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14

    Drug: NPC-14

  • Placebo comparator
    Placebo

    Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen

    Drug: Placebo

Interventions

  • DrugArbekacinStudies of ArbekacinArbekacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist. * An initial dose of NPC-14 will be half of that calculated by distribution volume:Vd based on patient age for safety reason. * After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14

    Also known as: Arbekacin

  • DrugPlacebo

    Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen

06

What researchers measure

Primary outcomes

  1. Safety and tolerability (Adverse events)

    Time frame: Up to 38 weeks (36 weeks treatment period and 2 weeks follow up period)

  2. Change of dystrophin expression rate in muscle tissues from the baseline assessment

    Time frame: At 37 weeks (1 week after from 36 weeks treatment period)

Secondary outcomes

  1. North Star Ambulatory Assessment

    Time frame: At 36 weeks

  2. Timed test (6MWT, time to walk/run 10 meters, time to climb/descent four steps, time to rise from the floor)

    Time frame: At 36 weeks

  3. Muscle strength (MMT, QMT)

    Time frame: At 36 weeks

  4. Dairy activities

    Time frame: At 36 weeks

  5. Biomarkers (CK, ALD)

    Time frame: At 36 weeks

07

Study locations

4 sites
  • Kobe university hospital, department of pediatrics
    Kobe, Hyogo prefecture 650-0017, Japan
  • Hyogo College of Medicine
    Nishinomiya, Hyogo prefecture 663-8501, Japan
  • National center of neurology and psychiatry
    Kodaira, Tokyo 187-8551, Japan
  • Tokyo Women's Medical University
    Shinjuku-ku, Tokyo 162-8666, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2013
First posted
Aug 7, 2013
Start
Aug 2013
Primary completionEst.
Oct 2015
CompletionEst.
Oct 2015
Last update
Sep 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01918384
Lead sponsor
Kobe University
Collaborators
Japan Medical Association, Nobelpharma
Responsible party
Yasuhiro Takeshima (MD, PhD, Kobe University) — Principal investigator
First posted
Aug 7, 2013
Start date
Aug 2013
Primary completion
Oct 2015 (estimated)
Completion
Oct 2015 (estimated)
Last update
Sep 3, 2015

Study contacts

Yasuhiro Takeshima, MD, PhD
principal investigator · Hyogo Medical University
Hirofumi Komaki, MD, PhD
study director · National center of neurology and psychiatry, department of child neurology, Muscular disease center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arbekacin

Start the discussion